Ajanta Pharma launches tablet to treat migraine

In a recent announcement, pharmaceutical major Ajanta Pharma has stated that it has launched Eletriptan Hydrobromide Tablet in the US market through its wholly-owned subsidiary, Ajanta Pharma USA Inc. The product was launched in two strengths, 20 mg and 40 mg tablets. The drug is a bioequivalent generic version of Relpax 1 Tablet that is used to treat migraines. 
 
Meanwhile, the stock was trading up by 0.37% at Rs 1,197 per share on the BSE at 1105 hours. It stock attracted a total traded volume of 2,09,575 shares and traded value of Rs 2,534.31 lakhs on the NSE at 1107 hours.
 
The drug is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, the company has 35 Abbreviated New Drug Applications (ANDAs) of which it has 19 final ANDA approvals, two tentative approvals and 14 ANDAs under review with the USFDA. So far it has launched 14 products in the US market.
 
The company’s consolidated revenue for the Q1FY18 remained flat at Rs 473 crores as against Rs 476 crores in the corresponding quarter last year. The PAT for the quarter was Rs 94.8 crores, showing a YoY decline of 20.7%.